Thoratec Schedules Second Quarter Conference Call, Webcast

Tue Jul 24, 2012 8:03am EDT

* Reuters is not responsible for the content in this press release.

Thoratec Schedules Second Quarter Conference Call, Webcast

PR Newswire

PLEASANTON, Calif., July 24, 2012 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that it will report its operating results for the second quarter of fiscal year 2012 on Wednesday, August 1.

The company will hold a conference call to discuss its financial results and operating activities, open to all interested parties, at 1:30 p.m., Pacific Daylight Time (4:30 p.m., Eastern Daylight Time), Wednesday, August 1, hosted by Gary F. Burbach, President and Chief Executive Officer.

The teleconference can be accessed by calling (719) 325-2445, passcode 2804068. Please dial in 10-15 minutes prior to the beginning of the call. The webcast will be available on the Internet at http://edge.media-server.com/m/p/9k74r7b7/lan/en, or http://www.thoratec.com.

A replay of the conference call will be available through Wednesday, August 8, via http://www.thoratec.com, or by telephone at (719) 457-0820, passcode 2804068.

Thoratec is a world leader in therapies to address advanced-stage heart failure. The company's products include the HeartMate® LVAS (Left Ventricular Assist System) and Thoratec® VAD (Ventricular Assist Device) with more than 20,000 devices implanted in patients suffering from heart failure. Thoratec also manufactures and distributes the CentriMag® and PediMag®/PediVAS® product lines. Thoratec is headquartered in Pleasanton, California. For more information, visit the company's website at http://www.thoratec.com.

Thoratec, the Thoratec logo, HeartMate, HeartMate II and GoGear are registered trademarks of Thoratec Corporation. CentriMag and PediMag are registered trademarks of Thoratec LLC, and PediVAS is a registered trademark of Thoratec Switzerland GmbH.

SOURCE Thoratec Corporation

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.